Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Register now >>

Non-Clinicians / Medical Office Support Staff / Industry Participants

Non-clinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff—may attend PAINWeekEnd on a space-available basis when accompanied by a clinician and will be put on a wait list. These non-clinicians must still pre-register. Participation in industry sponsored meal programs, however, is strictly limited to practicing licensed healthcare providers. Please make necessary arrangements for meals for office support staff. In order to maintain the professional nature of the conference, guests, spouses, friends, and/or family members who are not currently employed in the medical field may not attend PAINWeekEnd.

Venue

Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

The Hilton Austin
500 E 4th St.
Austin, TX 78701

View hotel website >>

Directions

Get Directions using Google Maps

Schedule

Faculty and courses are subject to change. Please refer to the online schedule below for the most recent course descriptions.

To view the schedule below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

*not certified for credit

Saturday, April 27, 2019

  • Registration and Exhibits

    Coffee will be served.

  • Involuntary Tapers: Legal, Ethical, and Clinical Concerns

    On March 15, 2016, the Centers for Disease Control and Prevention released their guideline with recommendations for primary care clinicians who prescribe opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Although most of the recommendations were supported by weak or very weak evidence, Recommendation # 7 stated that “clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids” if the harms outweigh the benefits. At least a year after the release of the CDC guideline, several states have implemented dosage triggers, ceilings, and involuntary tapers, and some healthcare professionals have reportedly subjected their patients to involuntary tapers because they believed the CDC guideline required it. Consequently, this session will explore the ethical, legal, and clinical concerns and potential harms associated with the involuntary tapering of patients on long-term opioid therapy as a result of a state law, regulation, or out of fear of regulatory sanction by the healthcare provider.

    • UAN: 0530-0000-19-010-L01-P
    • AANP Rx Hours: 0.00
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

  • BREAK & EXHIBITS

  • Nonopioid Analgesics, Adjuvants, and Antidepressants

    Nonopioid analgesics are oftentimes considered first-line therapy for most chronic pain syndromes. A strong understanding of these agents’ mechanism of action, pharmacokinetics, and toxicity profiles is paramount for today’s pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring pearls will be discussed.

    • UAN: 0530-0000-19-046-L01-P
    • AANP Rx Hours: 1.00
  • Embrace Changes and Prevent Overdose: A Basic Blueprint for Legal Risk Mitigation and Response

    Through the lens of medical expert testimony and case examples, attendees will learn core areas of risk mitigation with a focus on making electronic medical records and paper charting work for the practitioner to demonstrate prescribing in the usual course of professional practice. Overdose—a small word that packs a major punch, and a big reason for recent legal-regulatory changes in controlled substance prescribing and medication assisted treatment (MAT). Too often, prescribers are caught unprepared to respond to licensing board and legal inquiries surrounding overdose events. Many prescribers haven’t examined their own risk mitigation and documentation processes following changes to prescribing guidelines and rules, or even after learning about a patient’s emergency room visit or demise. Many prescribers also lack a structured approach to patient education to mitigate the risks associated with the use of controlled substances, errantly relying solely on a piece of paper to capture what should be a process of informed consent. Professional licensing board and criminal cases involving overdose events do not usually end well for the unprepared prescriber. Yet, there is much the prescriber can do proactively to signal his/her intent to prescribe for a legitimate medical purpose while acting in the usual course of professional practice and taking “reasonable steps” to mitigate abuse and diversion of controlled medication. This educational program includes lessons learned by the speaker through more than a decade of chart audits and legal case work. Attendees will have access to one or two sample templates that can be used to improve daily charting and to demonstrate adherence to risk evaluation, monitoring, and common documentation requirements. While prescribers cannot control what their patients do once they leave the medical office, they are responsible for establishing a safe framework for opioid prescribing, including a proper response when something goes wrong. This lecture will help the prescriber demonstrate thoughtful prescribing in the “usual course of professional practice” and improve the prescriber’s chances of minimizing legal liability associated with patient overdose.

    • UAN: 0530-0000-19-008-L01-P
    • AANP Rx Hours: 0.00
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

  • Cannabis vs Cannabinoids: The Politics of Medical Marijuana

    The subject of the medical use of cannabinoids has become an extremely hot topic. Unfortunately, there has been a tendency to equate medical cannabinoids with another very contentious topic: Medical Marijuana. In this presentation, the distinction between medical cannabinoids and medical cannabis will be explored. Specifically, the challenges facing prescribers who are being asked to prescribe medical marijuana will be examined.

    • UAN: 0530-0000-19-007-L01-P
    • AANP Rx Hours: 0.00
  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

  • Rational Polypharmacy

    Multidrug therapy, also known as rational polypharmacy, has been a part of treatment approaches for chronic pain for many years. This course will review the concept of rational polypharmacy as it applies to the treatment of migraine, neuropathic pain, and musculoskeletal pain conditions.

    • UAN: 0530-0000-19-032-L01-P
    • AANP Rx Hours: 0.00
  • Get Your Specimens in Order: Timely Use of Test Results

    Drug testing is part of a complete patient evaluation and ongoing risk monitoring in most medical practice settings when treatment involves long-term use of controlled medication. Today’s licensing board guidelines and rules, and position papers published by professional societies, make clear that drug testing should be performed and test results should be used in a timely fashion to guide medical decision-making prior to initiating controlled substance therapy, especially in the nonterminal, subacute, and chronic settings, and in ongoing patient risk monitoring and corresponding treatment plan adjustments. If a provider has his/her own clinical laboratory, or certain types of business arrangements with an independent clinical laboratory, failure to appreciate a new federal law impacting clinical laboratory or payor policies setting forth documentation requirements for medically necessary testing may spell financial disaster for the provider. Providers should review their current drug testing practices and, where applicable, coverage and reimbursement policies, to improve their ability to demonstrate quality patient care and adherence to the ever-developing body of laws and regulations governing controlled substance prescribing. Providers in business relationships with independent clinical laboratories or laboratory set-up companies should be generally familiar with a new federal law that may render suspect or unlawful certain aspects of these business arrangements, which may potentially expose the provider to allegations of fraud and abuse or recoupment for overpayments. Providers who proactively address any deficiencies or weaknesses in their use of drug testing in the context of controlled substance prescribing will largely minimize the potential for bad patient outcomes and related legal liability associated with controlled substance prescribing and the financial aspects of clinical laboratory. Using a series of “do this, not that” cases, attendees will learn how to distinguish poor workflow and documentation in drug testing from efficient and effective assimilation of standards of care and payor policies on medical necessity into their personal styles of patient evaluation and ongoing care. Attendees will be given two basic tools to reinforce learning objectives: a workflow template and an adaptable form to help the provider make timely and reasonably prudent ongoing treatment decisions, all of which may help the provider minimize the potential for an overdose event.

    • UAN: 0530-0000-19-009-L01-P
    • AANP Rx Hours: 0.00

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!